Article
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Blood - 15 May 2004
Smith B Douglas, Levis Mark, Beran Miloslav, Giles Francis, Kantarjian Hagop, Berg Karin, Murphy Kathleen M, Dauses Tianna, Allebach Jeffrey, Small Donald
Abstract excerpt
Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30% of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure rates from standard chemotherapy-based treatment. Targeting the mutation by inhibiting the tyrosine kinase activity o...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.